Wednesday, August 31, 2016

GeneNews and JTS Health in business acceleration pact

GeneNews and JTS Health in business acceleration pact

March 31, 2016 by · Leave a Comment 

Tweet GeneNews (TSX:GEN) has entered into a collaboration agreement with JTS Health Partners of Atlanta to accelerate adoption of GeneNews’ menu of proprietary cancer tests, including its lead ColonSentry blood-test for assessing an individual’s current risk for colorectal cancer. JTS, a leading national healthcare management consulting and professional services firm, will also work to maximize […]

Rodman starts VolitionRx at buy

Rodman starts VolitionRx at buy

February 1, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw has initiated coverage of VolitionRx (NASDAQ:VNRX) with a “buy” rating and a 12-month price target of $12. The stock closed at $3.77 on Friday. “In our view, the company’s blood-based NuQ screening test for colorectal cancer, based on its proprietary nucleosomics epigenetic biomarker platform, is differentiated from traditional detection methods and […]

HCW starts Biocept at buy

HCW starts Biocept at buy

August 19, 2015 by · Leave a Comment 

Tweet H.C. Wainwright has initiated coverage of Biocept (NASDAQ:BIOC) with a “buy” rating and $4 price target. The stock closed at $1.96 on Tuesday. Biocept is a commercial-stage company in the emerging field of liquid biopsy, focusing on the capture, enumeration and analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) from a blood […]

GeneNews’ IDL jv highlighted on CEO Clips

GeneNews’ IDL jv highlighted on CEO Clips

July 3, 2014 by · Leave a Comment 

Tweet James Howard-Tripp, executive chairman of GeneNews (TSX:GEN), has been featured on Business Television’s CEO Clips discussing the company’s new U.S. joint venture, Innovative Diagnostic Laboratory, or IDL. IDL’s mission is to provide a comprehensive menu of advanced blood tests that aid in early cancer detection, guide cancer treatment protocols, and monitor remission and recurrence. […]

GeneNews’ IDL off to flying start

GeneNews’ IDL off to flying start

May 20, 2014 by · Leave a Comment 

Tweet GeneNews’ (TSX:GEN) recently formed U.S. joint venture, Innovative Diagnostic Laboratory (IDL), took a huge step forward in the first quarter in its goal of becoming a leader in molecular diagnostics and personalized medicine. “With a successful limited scale launch of IDL in the fourth quarter of 2013, full scale-up activities began in the first […]

GeneNews IDL JV posts big jumps in tests processed

GeneNews IDL JV posts big jumps in tests processed

May 15, 2014 by · Leave a Comment 

Tweet GeneNews’ (TSX:GEN) recently formed U.S. joint venture, Innovative Diagnostic Laboratory (IDL), has reported a 346% sequential jump in tests processed during the first quarter, compared with the 2013 fourth quarter. IDL processed 14,680 tests at its CLIA-approved lab in Richmond, VA during the initial quarter this year and “growth is expected to continue throughout the […]

Zacks ups GeneNews price target to $3

Zacks ups GeneNews price target to $3

March 6, 2014 by · Leave a Comment 

Tweet Zacks Investment Research has raised its price target for “outperform-rated” GeneNews (TSX:GEN) to $3 from $2, saying revenue growth will accelerated in 2014 and beyond from a recently formed U.S. joint venture, Innovative Diagnostic Laboratory (IDL). Shares of GeneNews closed at $1.09 on Wednesday. “Specifically, we estimate revenue from IDL will be $2.6-million [in […]

Verisante expands its sales and marketing team

Verisante expands its sales and marketing team

February 26, 2014 by · Leave a Comment 

http://www.youtube.com/watch?v=gV2Fglh4-94′]

Tweet Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) has hired Jason Mangler as director of sales to guide the company’s worldwide sales and marketing strategy and also hired Kim Ellis as its sales representative for Western Canada. As director of sales, Mr. Mangler will supervise the company’s sales and marketing team to identify market opportunities and fulfill market […]

GeneNews provides IDL jv progress update, appoints director

GeneNews provides IDL jv progress update, appoints director

November 14, 2013 by · Leave a Comment 

Tweet In its Q3 results release, GeneNews (TSX:GEN) provided a progress update and announced the appointment of Floyd C. Dent to its Board. In a statement, executive chairman James Howard-Tripp said start-up operations at Innovative Diagnostic Laboratory’s (IDL) Richmond, VA lab, which were initiated in the third quarter, have gone smoothly. “Soon after successfully obtaining CLIA […]

CytRx awaiting soft tissue sarcoma data in December

CytRx awaiting soft tissue sarcoma data in December

October 15, 2013 by · Leave a Comment 

Tweet What if it were possible to deliver a broad range of potent cancer drugs more optimally, enhancing both their safety and efficacy? That’s the question CytRx (NASDAQ:CYTR) hopes to answer this December when it plans to report top-line Phase 2b data from a global clinical trial of its lead drug, aldoxorubicin, as a first-line […]

Next Page »

Email Newsletters with Constant Contact
Google+